Centocor, Inc.
800 Ridgeview Drive
Horsham
Pennsylvania
19044
United States
Tel: 610-651-6000
Fax: 610-651-6100
Website: http://www.centocor.com/
About Centocor, Inc.
Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Centocor products have also saved lives in the treatment of heart attacks and have been used to reduce risk of cardiac events in interventional cardiology.Centocor continues to pioneer new pathways in biomedical research and development. Drug discovery and development efforts focus on the following therapeutic areas: I.M.I.D. (Immune Mediated Inflammatory Diseases) hematology/oncology, infectious diseases, metabolic diseases, inflammatory bowel disorders, pulmonary disorders, central nervous system disorders, dermatology, rheumatology and cardiovascular disease. Centocor is looking for novel approaches that address the pathology of these diseases.
The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor, Inc. is a wholly owned subsidiary of Johnson & Johnson, a worldwide manufacturer of healthcare products.
Products:
REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent approved for the treatment of both rheumatoid arthritis (RA) and Crohn's disease (CD) in North America, the European Union (EU) and Japan. In the EU and in the U.S., REMICADE is approved for the treatment of active ankylosing spondylitis (AS) and psoriatic arthritis.
Senior Officers: Julie McHugh, President
Last Updated: 07-13-05
76 articles about Centocor, Inc.
-
Schering-Plough Corporation and Centocor, Inc. REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
6/15/2007
-
Centocor, Inc. and Schering-Plough Corporation Release: Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
6/7/2007
-
Centocor, Inc. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
5/24/2007
-
The Day In Review: Biosite Incorporated Takes $85 Offer From Beckman Coulter, Inc.
3/26/2007
-
Centocor, Inc. Release: European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
3/26/2007
-
Centocor, Inc. Release: REMICADE(R) Therapy Shown To Improve Productivity In Patients Treated For Chronic Plaque Psoriasis
2/5/2007
-
Centocor, Inc. Release: New Analyses Reinforce Efficacy Of REMICADE(R) In Treatment Of Severe Psoriasis
2/5/2007
-
Epigenomics AG To Discover Biomarkers In R&D Collaboration With Centocor, Inc.
1/4/2007
-
Centocor, Inc. Release: Data Show Treatment With Remicade(R) Reduced Hospitalizations For Ulcerative Colitis Patients By Half
10/23/2006
-
FDA Expands Centocor, Inc.'s REMICADE(R) Indication For Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission And Mucosal Healing
10/19/2006
-
Centocor, Inc. Enters Into Oncology Target Licensing Agreement Wth Centocor Research And Development, Inc.
10/11/2006
-
FDA Approves Centocor, Inc.'s REMICADE(R) For Treatment Of Chronic Severe Plaque Psoriasis: Marks Major Milestone For Patients With High Disease Burden
9/27/2006
-
FDA Expands Centocor, Inc.'s REMICADE(R) Psoriatic Arthritis Indication: Anti-TNF Shown To Inhibit Joint Damage And Improve Physical Function
8/14/2006
-
Centocor, Inc. Release: FDA Accepts REMICADE(R) Supplemental Biologics License Application For Inhibition Of Structural Damage And Improving Physical Function In Patients With Psoriatic Arthritis
6/21/2006
-
ViaCell, Inc. Announces Cardiac Collaboration With Centocor Research And Development, Inc.
6/13/2006
-
Centocor, Inc. Release: New Analysis Showed Ulcerative Colitis Patients In Clinical Remission Had Higher Rates Of Employment And Lower Rates Of Disability
5/24/2006
-
Centocor, Inc. Release: FDA Grants Priority Review Of REMICADE(R) For The Treatment Of Children With Active Crohn's Disease
4/4/2006
-
Centocor, Inc. Release: REMICADE(R) Is First Biologic Approved In European Union To Treat Ulcerative Colitis
3/9/2006
-
Centocor, Inc. Release: REMICADE(R) Phase 3 Data Show Rapid And Significant Improvement And Long-Term Response In The Treatment Of Moderate To Severe Psoriasis
3/6/2006
-
Centocor, Inc. Release: REMICADE(R) Phase 3 Data Show Rapid And Significant Improvement And Long-Term Response In The Treatment Of Moderate To Severe Psoriasis
3/3/2006